What Should Investors Know About Zimmer Biomet (ZBH) Stock?

By Susan Ramirez • Thursday, December 21 12:00 • Permanent Link

Zimmer Biomet, a large-cap Specialty Industrial Machinery stock, moved 0.2% this morning. Here are some facts about the company that we're keeping an eye on:

Zimmer Biomet has logged a -5.4% 52 week change, compared to 22.9% for the S&P 500
ZBH has an average analyst rating of hold and is -7.26% away from its mean target price of $129.63 per share
Its trailing earnings per share (EPS) is $2.26, which brings its trailing Price to Earnings (P/E) ratio to 53.2. The Health Care sector's average P/E ratio is 30.21
The company's forward earnings per share (EPS) is $7.94 and its forward P/E ratio is 15.1
The company has a Price to Book (P/B) ratio of 2.01 in contrast to the Health Care sector's average P/B ratio is 4.08
ZBH has reported YOY quarterly earnings growth of -16.3% and gross profit margins of 0.7%
The company's free cash flow for the last fiscal year was $945.7 Million and the average free cash flow growth rate is -6.6%
Zimmer Biomet's revenues have an average growth rate of -0.9% with operating expenses growing at -1.7%. The company's current operating margins stand at 12.3%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.